Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Organogenesis Holdings Inc. and its officers or directors, following a significant stock price drop due to regulatory changes affecting the company [1][3]. Group 1: Company Overview - Organogenesis Holdings Inc. is a company listed on NASDAQ under the ticker ORGO [1]. - The company specializes in skin substitute grafts and cellular and tissue-based products [3]. Group 2: Regulatory Impact - On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations (LCDs) related to Organogenesis's products, which were set to take effect in the following year [3]. - The withdrawal of these LCDs is expected to increase competition for Organogenesis, as over 300 other market participants will now be able to compete more freely in the market [3]. Group 3: Market Reaction - Following the announcement of the withdrawal of the LCDs, Organogenesis's stock price fell by $0.59 per share, representing a decline of 10.14%, closing at $5.28 per share on December 30, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On November 14, 2025, Anavex announced a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the Marketing Authorisation Application (MAA) for blarcamesine [3]. - Following this announcement, Anavex's stock price dropped by $2.05 per share, representing a decline of 35.94%, closing at $3.65 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has a track record of recovering multimillion-dollar damages awards for class members [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Ultragenyx Pharmaceutical Inc. and its officers or directors, following disappointing Phase 3 study results for setrusumab, which led to a significant drop in the company's stock price [1][3][4]. Group 1: Company Performance - Ultragenyx announced results from two Phase 3 studies for setrusumab, a treatment for bone metabolism conditions, on December 29, 2025 [3]. - Neither study achieved statistical significance for the primary endpoints related to the reduction in annualized clinical fracture rate compared to placebo or bisphosphonates [3]. - Both studies met their secondary endpoints, showing significant improvements in bone mineral density against comparators [3]. Group 2: Stock Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $2.02 per share, representing a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Ultragenyx and its management [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ventyx Biosciences, Inc. and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Ventyx announced a revision of its guidance for topline data release from the interim analysis of its Phase 2 study of VTX2735, now expected in Q1 2026 [3]. - The CEO indicated that this shift allows for the introduction of dose-ranging studies with a new once-daily formulation and expansion into Canada, the EU, and the UK, which is believed to accelerate Phase 3 timelines [3]. - Following this announcement, Ventyx's stock price decreased by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Ventyx to discuss claims related to potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM, maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [2] - Following the announcement of the amended acquisition agreement, SNDL's stock price fell by $0.29 per share, or 13.12%, closing at $1.92 per share on December 15, 2025 [3]

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [2] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating ongoing communication between the company and the agency [2] - Galectin plans to pursue a follow-up Type C meeting with the FDA to finalize the remaining components of its next clinical trial design, although key aspects of the trial design remain unresolved [2] Group 2: Market Reaction - Following the announcement regarding the FDA's response, Galectin's stock price fell by $1.78 per share, representing a 28.9% decrease, closing at $4.38 per share on December 19, 2025 [3]

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential securities fraud and unlawful business practices following disappointing Phase 3 study results for its treatment setrusumab, which led to a significant drop in stock price [1][3][4]. Group 1: Company Performance - Mereo announced results from two Phase 3 studies for setrusumab, a treatment aimed at conditions affecting bone metabolism [3]. - Neither study met the primary endpoints of reducing the annualized clinical fracture rate compared to placebo or bisphosphonates, although both achieved secondary endpoints related to improvements in bone mineral density with strong statistical significance [3]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, a decrease of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Mereo investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its executives following the FDA's rejection of the company's request for accelerated approval of its treatment INO-3107 [1][3]. Group 1: FDA Announcement - On December 29, 2025, the FDA accepted Inovio's Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio announced it does not plan to pursue approval under the standard review timeline and intends to meet with the FDA to discuss options for accelerated approval [3]. Group 2: Stock Market Reaction - Following the FDA announcement, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $2.29 per share on December 29, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Outset Medical and its officers/directors, following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On November 10, 2025, Outset Medical reported non-GAAP earnings per share of -$0.69, missing consensus estimates by $0.03 [3]. - The company generated revenue of $29.43 million for the third quarter of 2025, which was $1.27 million below consensus estimates [3]. - Outset Medical revised its 2025 revenue outlook to a range of $115 million to $120 million, down from a previous range of $122 million to $126 million, citing delays in closing large opportunities [3]. Stock Market Reaction - Following the announcement of the financial results, Outset Medical's stock price fell by $5.85 per share, or 48.47%, closing at $6.22 per share on November 11, 2025 [3].